Kiwoom Securities Co., Ltd. acquired approximately 1.8% stake in Biocore Co., Ltd. from SCL Healthcare Co., Ltd. and Kyungryul Lee for approximately KRW 1.6 billion.
August 02, 2016
Share
Kiwoom Securities Co., Ltd. (KOSE:A039490) acquired approximately 1.8% stake in Biocore Co., Ltd. from SCL Healthcare Co., Ltd. and Kyungryul Lee for approximately KRW 1.6 billion on July 28, 2016. As part of the transaction, Kiwoom Securities acquired approximately 0.11 million shares from SCL Healthcare and 18,846 shares from Kyungryul Lee at a price of KRW 13,000 per share in an off-market transaction. Post-transaction, SCL will retain 70,000 shares in Biocore. In related transactions, Seunghyun Lee acquired approximately 2.67% stake in Biocore Co., Ltd. from K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1, MAVI New Growth Good Corporation Investment Fund No. 2 for approximately KRW 2.1 billion.
Kiwoom Securities Co., Ltd. (KOSE:A039490) completed the acquisition of approximately 1.8% stake in Biocore Co., Ltd. from SCL Healthcare Co., Ltd. and Kyungryul Lee on July 28, 2016.
Invites Biocore Co Ltd, formerly BioCore Co Ltd, is a Korea-based company mainly engaged in the provision of medical examination services. The Company operates its business through two segments. The New Drug Development Business segment is involved in the provision of bioequivalence testing, drug in vivo kinetics research, drug analysis in biological samples, toxicity kinetics testing, microanalysis in pharmaceuticals, comparative dissolution testing, and clinical trial consulting. The Biotechnology Business segment is engaged in the provision of customized genome analysis services and the manufacture and sale of diagnostic kits. The Companyâs products are sold under the brand of Bio-Core.
Kiwoom Securities Co., Ltd. acquired approximately 1.8% stake in Biocore Co., Ltd. from SCL Healthcare Co., Ltd. and Kyungryul Lee for approximately KRW 1.6 billion.